Status:
UNKNOWN
PiXL for Correction of Hyperopia
Lead Sponsor:
Gemini Eye Clinic
Conditions:
Hyperopia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This clinical study aims to investigate the efficacy and safety of PiXL in the refractive correction of low hyperopia.
Detailed Description
This clinical study aims to investigate the efficacy and safety of PiXL in the refractive correction of low hyperopia.Slightly modified settings from previously published study is applied to eyes with...
Eligibility Criteria
Inclusion
- low hyperopia of spherical equivalent from +0.5 up to +1.75 D sp. eq.
- astigmatism up to 0.75 Dcyl
- corneal thickness above 400 µm
- endothelial cell density above 1500 cell/mm2
Exclusion
- any prior corneal surgery or any eye surgery within the last 3 months,
- any corneal pathology e.g. corneal scar or dystrophy
- unstable refraction
- patient not able to understand and sign informed consent
- patients with connective tissue disorder or uncontrolled diabetes
- pregnant or lactating women
- aphakic eyes or pseudophakic eyes without UV blocking IOL
Key Trial Info
Start Date :
December 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2021
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT03805425
Start Date
December 1 2016
End Date
March 1 2021
Last Update
February 3 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gemini Eye Clinic
Zlín, Czechia, 760 01